Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses

International Journal of Fertility and Women's Medicine

Volumn 52, Issue 2-3, 2007, Pages 93-96

  Carranza Lira, Sebastián ^a   Gooch, Ana Luz MacGregor ^a   Saldivar, Nadia ^a   Osterwalder, Max Saráchaga ^b  

^a Hospital de Ginecología y Obstetricia Luis Castelazo Ayala   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Conjugated esterified estrogens; Low dose; Raloxifene; Symptoms

Indexed keywords

CONJUGATED ESTROGEN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

AGED; ANALYSIS OF VARIANCE; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG COMBINATION; ESTROGEN THERAPY; FEMALE; HOT FLUSH; HUMAN; INSOMNIA; METABOLISM; MIDDLE AGED; POSTMENOPAUSE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WOMEN'S HEALTH;

AGED; ANALYSIS OF VARIANCE; ANXIETY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; POSTMENOPAUSE; QUALITY OF LIFE; QUESTIONNAIRES; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; WOMEN'S HEALTH;

EID: 42949129523     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Murillo A, Carranza-Lira S, Martínez-Trejo N, et al: Variables epidemiológicas en la mujer posmenopáusica. Ginecol Obstet Mex 67:478-483, 1999.
2. Lauritzen C: The female climacteric syndrome: significance problems, treatment. Acta Obstet Gynecol Scand Supl 51:47-61, 1976.
3. Carranza-Lira S, Cortés-Fuentes E: Modification of vasomotor symptoms after different treatment modalities in the postmenopause. Int J Gynaecol Obstet 73:169-171, 2001. (Pubitemid 32385378)
4. Hlatky MA, Boothroyd D, Vittinghoff E, et al: Quality of life and depressive symptoms in post-menopausal women after receiving hormone therapy: results from the Herat and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 287:591-597, 2002. (Pubitemid 34252010)
5. Delmas PD, Bjarnason NH, Mitlak BH, et al: Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647, 1997. (Pubitemid 27510100)
6. Barrett-Connor E, Grady D, Sashegyi A: Raloxifene and cardiovascular events in osteoporotic post-menopausal women. Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287:847-857, 2002.
7. Cauley JA, Norton L, Lippman ME, et al: Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple Outcomes of Raloxifene Evaluation. Breast Cancer Res Treat 65:125-134, 2001. (Pubitemid 32193616)
8. Gordon S, Walsh BW, Ciaccia AV, et al: Transition from estrogen-progestin to raloxifene in post-menopausal women: effect on vasomotor symptoms. Obstet Gynecol 103:267-273, 2004.
9. Neven P, Quail D, Levrier M, et al: Uterine effects of estrogen plus progestin therapy and raloxifene: adjudicated results from the EURALOX study. Obstet Gynecol 103(5 Pt 1):881-891, 2004. (Pubitemid 40458988)
10. Carranza-Lira S, Martínez-Chéquer JC, Santa Rita EMT, et al: Endometrial changes according to hormone replacement therapy schedule. Menopause 5:86-89, 1998. (Pubitemid 28283036)
11. Carranza-Lira S, Reyes PBP, Chan VR: SUMEVA, a new system of climacteric symptom evaluation audits correlation with FSH and estradiol levels. Int J Fertil 51:140-144, 2006.
12. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321-333, 2002.
13. Gambacciani M, Ciaponi M, Cappagli B, et al: Effects of low-dose continuous combined estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density and metabolism in postmenopausal women. Am J Obstet Gynecol 185:1180-1185, 2001. (Pubitemid 33097384)
14. Rebar RW, Trabal J, Mortola J: Low-dose esterified estrogens (0.3mg/day): long-term and short-term effects on menopausal symptoms and quality of life in postmenopausal women. Climacteric 3:176-182, 2000.
15. Carranza-Lira S, MacGregor GAL, Velasco-Diaz G, et al: Low and ultra low-dose estrogen therapy for climacteric symptom control preliminary report. Int J Fertil 51:171-175, 2006.
16. Daly E, Vessey MP, Hawkins MM, et al: Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348:977-980, 1996. (Pubitemid 26340751)
17. Smith NL, Heckbert SR, Lemaitre RN, et al: Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 292:1581-1587, 2004. (Pubitemid 39314964)